Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 10/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093718 | 0.85 | OPRK1 (0.40) | SUV39H2PDE10APIM1PIM3PIM2 | |
| SCHEMBL2092020 | 0.85 | OPRK1 (0.40) | SUV39H2PDE10APIM1PIM3PIM2 | |
| SCHEMBL7837069 | 0.84 | SYK (0.39) | MAP4K4SUV39H2PDE10AJAK3BTK | |
| SCHEMBL2095463 | 0.81 | NPC1 (0.46) | — | |
| SCHEMBL7836956 | 0.77 | HRH2 (0.39) | MAP4K4SUV39H2PDE10ASYK | |
| SCHEMBL10390924 | 0.75 | OPRK1 (0.40) | — | |
| SCHEMBL2095014 | 0.74 | SUV39H2 (0.42) | SUV39H2BTKSYK | |
| SCHEMBL30267297 | 0.74 | JAK3 (0.51) | MAP4K4PDE10AJAK3BTKSYK | |
| SCHEMBL2023298 | 0.74 | ALDH1A1 (0.45) | — | |
| SCHEMBL31310738 | 0.73 | HPGD (0.42) | SUV39H2PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | MAP4K4 2295/4885SUV39H2 4289/4885PDE10A 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.